#MultipleMyeloma Archives

ASH 2024 | Dr. Wenming Chen: Precision and Immune-Targeted Therapies to Overcome R/R MM Challenges

By Mourabit Halima 2024.12.31

Editor's Note: The 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego from December 7 to 10, 2024. This prestigious event brought together global…

Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China

By Mourabit Halima 2024.03.20

Introduction: Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a pivotal therapeutic modality for lymphoma and multiple myeloma (MM), offering promising outcomes in improving patient prognosis. In China, the…

$Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results$

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

By Mourabit Halima 2024.03.17

Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…

Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach

By Mourabit Halima 2024.03.15

Editor's note: In patients with newly diagnosed multiple myeloma (NDMM), infections pose a significant threat to morbidity and mortality, particularly within the initial months post-diagnosis. Immunoparesis, characterized by reduced levels…

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

By Mourabit Halima 2024.03.07

In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Frontiers In Oncology. The title of the…

Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach

By Mourabit Halima 2024.02.28